ERBB2 and ovarian carcinoma: CPS ≥ 1 (≥ 5 in gastric cancer) was confirmed in 58 (10.5%) patients (e.g., CPS‐positive ovarian cancer recommended for pembrolizumab following KEYNOTE 100 trial results), HER2 low expression (IHC 1+ or IHC 2+, ISH negativity) was detected in 21 (3.8%) patients (e.g., trastuzumab deruxtecan in HER2‐low non‐breast tumors), and androgen receptor positivity was observed in one patient [15, 16].